title: Left ventricular performance after intravenous infusion of captopril in patients with congestive heart failure.
abstract: BACKGROUND
  Although oral administration of captopril, an angiotensin-converting enzyme inhibitor, is effective for the treatment of congestive heart failure (CHF), the effect of its intravenous (iv) administration is not well known.
  
  
  RESULTS
  Ten patients (age range 48-72 years), with CHF belonging to the second and third NYHA class, were given an iv bolus of 25 mg of captopril. Before and 30 minutes after the infusion of captopril, a number of parameters of the left ventricular function were evaluated by echocardiography IREX 3 M-B Mode. Eight patients showed a significant improvement of left ventricular performance indices. In fact, the ejection fraction (13.8%, p < 0.05), the cardiac output (24%, p < 0.001), the circumferential shortness fraction (29.9%, p < 0.05), and the fraction shortening (16.0%, p < 0.005) increased significantly, whereas the end-systolic diameter (21%, p < 0.001), the endsystolic stress (23.8%, p < 0.01) and the left ventricle ejection time (4.8%, p < 0.05) decreased significantly. Systolic and diastolic blood pressure values also underwent a significant reduction by 17% and 11% (p < 0.01 and p < 0.05 respectively). No evident correlation between the improvement of the left ventricular function and the basal renin rates was noticed.
  
  
  CONCLUSIONS
  A significant improvement of parietal kinesis was observed especially in those segments which showed movement abnormalities (hypokinesia and akinesia) and in many cases this was detected by M-B Mode echocardiography. Our findings may be the result of the following factors: 1) reduction of parietal stress; 2) increased district coronary flow; 3) inhibition of tissue renin-angiotensin-aldosterone system; and 4) "scavenging" action exerted by the SH group of captopril.
authors.affiliation: First Department of Internal Medicine, University of Catania Medical School, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Arcidiacono
authors.forename: G O
authors.initials: GO
authors.lastname: Asmundo
authors.forename: E
authors.initials: E
authors.lastname: Battaglia
authors.forename: E
authors.initials: E
authors.lastname: Bordignon
authors.forename: A E
authors.initials: AE
authors.lastname: Calogero
authors.forename: S
authors.initials: S
authors.lastname: Cuscunà
authors.forename: S
authors.initials: S
authors.lastname: Floridia
authors.forename: G
authors.initials: G
authors.lastname: Vigo
authors.forename: A M
authors.initials: AM
authors.lastname: Ossino
authors.forename: G
authors.initials: G
authors.lastname: Gurgone
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D002216:Captopril / Q000008:administration & dosage / Q000627:therapeutic use*; D004452:Echocardiography; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril